Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

FDA reject etoricoxib for OA

The Food and Drugs Administration (FDA) has issued a Non Approvable Letter for etoricoxib (Arcoxia®) in osteoarthritis (OA) according to the manufacturer's website.

Etoricoxib is a Cox-II selective non-steroidal anti-inflammatory that is available and licensed in the UK for osteoarthritis, rheumatoid arthritis and gout. The FDA rejected the application for a licence in OA and requested additional data in support of the benefit-to-risk profile.

Action: Etoricoxib is licensed for OA in the UK, however it may be prudent to restrict use of this drug in OA based on the cautious approach taken in America.

Share 'FDA reject etoricoxib for OA' on Email Share 'FDA reject etoricoxib for OA' on Delicious Share 'FDA reject etoricoxib for OA' on Digg Share 'FDA reject etoricoxib for OA' on Facebook Share 'FDA reject etoricoxib for OA' on Google+ Share 'FDA reject etoricoxib for OA' on reddit Share 'FDA reject etoricoxib for OA' on StumbleUpon Share 'FDA reject etoricoxib for OA' on Twitter

atomic-wealth

No Comments to “FDA reject etoricoxib for OA”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,320 spam comments.

atomic-wealth
fond-illness
summer